Lam Research stock pulls back after-hours as fresh $260 Buy call runs into Jan. 28 earnings

Lam Research stock pulls back after-hours as fresh $260 Buy call runs into Jan. 28 earnings

New York, January 7, 2026, 17:02 ET — After-hours

  • Lam Research shares ended down 1.9% at $203.08, a day after hitting a 52-week high
  • Aletheia Capital initiated coverage with a Buy rating and a $260 price target
  • Lam set Jan. 28 for its December-quarter earnings call

Lam Research (LRCX.O) shares ended down 1.9% on Wednesday and were last at $203.08 in after-hours trade, after swinging between $200.04 and $206.77 in the regular session.

The drop snapped a three-day winning streak and left the chip-tool maker about 3.5% below its $210.45 52-week high, set a day earlier. Volume climbed to 14.8 million shares, above its 50-day average, as the S&P 500 and Dow slid and chip-related names also softened. Marketwatch

Why it matters now: Lam has been a momentum name in chip equipment, and the stock is close enough to its highs that research notes can move it fast in either direction. The next earnings update is also close, so traders are less willing to chase late-day strength.

Aletheia Capital started coverage on Tuesday with a Buy rating and a $260 price target, analyst Warren Lau wrote, citing “industry leading process tools” and market-share gains tied to artificial intelligence and high-performance computing (HPC). The target implies roughly 28% upside from Wednesday’s close. Streetinsider

Wednesday looked more like digestion than a fresh view on fundamentals. Lam held above $200 at the session low, but it could not reclaim the prior day’s highs as the broader tape turned defensive.

The company, based in Fremont, California, said it will host its quarterly financial conference call and webcast on Wednesday, Jan. 28 at 2 p.m. Pacific time (5 p.m. Eastern). Stock Titan

That call will likely settle the argument behind the week’s swings: whether demand for Lam’s etch and deposition tools is holding up as chipmakers weigh new spending on advanced chips and packaging, and how sticky service revenue looks if orders slow.

But the setup cuts both ways. A bullish initiation and a near-term earnings date do not remove the usual risks for chip-equipment stocks — customer capex can turn quickly, and guidance can disappoint even when the long-term story stays intact.

Next up: Lam’s December-quarter results and outlook on Jan. 28, with investors watching the company’s tone on 2026 demand and any sign that the latest run in the shares is getting ahead of orders.

Stock Market Today

  • Exelixis appears undervalued: DCF fair value at $214.52 vs $46.19 price
    January 8, 2026, 9:21 AM EST. Exelixis (EXEL) trades near $46.19 as investors weigh growth prospects in US pharma. Over the past year, shares are up 33.9%, with 3-year and 5-year returns of 175.1% and 89.5%, while the last week and month show gains. The stock carries a 5/6 valuation check from our framework. Our DCF model, a Two-Stage Free Cash Flow to Equity approach, yields an intrinsic value of $214.52 per share, implying the current price is undervalued by 78.5%. The model assumes latest twelve-month FCF of about $651.6 million and projected FCF near $2.0 billion by 2030, with 2026-2035 cash flows between $803.7 million and $3.2 billion. Investors also consider whether the P/E ratio aligns with growth expectations.
Lockheed Martin stock slides after Patriot missile deal, Goldman sticks to $430 sell target
Previous Story

Lockheed Martin stock slides after Patriot missile deal, Goldman sticks to $430 sell target

Boeing stock slips after-hours despite Alaska Airlines’ record jet order, with earnings next on Jan. 27
Next Story

Boeing stock slips after-hours despite Alaska Airlines’ record jet order, with earnings next on Jan. 27

Go toTop